| 产品描述： | Maropitant is a selective and orally active neurokinin (NK1) receptor antagonist. Maropitant acts by blocking the binding of substance P within the emetic center and the chemoreceptor trigger zone (CRTZ). Maropitant is highly effective in preventing vomiting |
| 靶点： |
Neurokinin Receptor;Neurokininreceptor |
| 体内研究： |
Treatment with 1 mg/kg Maropitant citrate, significantly reduces the size of ulcerative dermatitis (UD) lesions in mice. Intravenous Maropitant decreases MAC by 16%. In contrast, epidural administration of either saline or Maropitant does not change the MAC (2.17% and 1.92 %, respectively). |
| 参考文献： |
1. Hay Kraus BL. Efficacy of maropitant in preventing vomiting in dogs premedicated with hydromorphone. Vet Anaesth Analg. 2013 Jan;40(1):28-34. 2. Lesman SP, Boucher JF, Grover GS, et al. The pharmacokinetics of maropitant citrate dosed orally to dogs at 2 mg/kg and 8 mg/kg once daily for 14 days consecutive days. J Vet Pharmacol Ther. 2012 Nov 20. 3. Alvillar BM, Boscan P, Mama KR, et al. Effect of epidural and intravenous use of the neurokinin-1 (NK-1) receptor antagonist maropitant on the sevoflurane minimum alveolar concentration (MAC) in dogs. Vet Anaesth Analg. 2012 Mar;39(2):201-5. 4. Ramsey DS, Kincaid K, Watkins JA et al. Safety and efficacy of injectable and oral maropitant, a selective neurokinin 1 receptor antagonist, in a randomized clinical trial for treatment of vomiting in dogs. J Vet Pharmacol Ther. 2008 Dec;31(6):538-43. doi 5. Benchaoui HA, Cox SR, Schneider RP et al. The pharmacokinetics of maropitant, a novel neurokinin type-1 receptor antagonist, in dogs. J Vet Pharmacol Ther. 2007 Aug;30(4):336-44. 6. Maropitant |
| 溶解性： |
Soluble in DMSO |
| 保存条件： |
-80℃（运输条件：冰袋低温运输） |
| 配置溶液浓度参考： |
|
1mg |
5mg |
10mg |
| 1 mM |
2.134 ml |
10.668 ml |
21.337 ml |
| 5 mM |
0.427 ml |
2.134 ml |
4.267 ml |
| 10 mM |
0.213 ml |
1.067 ml |
2.134 ml |
| 50 mM |
0.043 ml |
0.213 ml |
0.427 ml |
|
| 注意： |
部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京